Vanda Pharmaceuticals Inc.
VNDA
$5.04
$0.122.44%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 11.61% | -5.59% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.61% | -5.59% | |||
| Cost of Revenue | 1.53% | -6.66% | |||
| Gross Profit | 12.18% | -5.53% | |||
| SG&A Expenses | 4.55% | -4.82% | |||
| Depreciation & Amortization | 0.06% | -0.06% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.21% | -3.25% | |||
| Operating Income | 6.55% | -8.42% | |||
| Income Before Tax | -4.05% | -13.20% | |||
| Income Tax Expenses | -72.28% | 7.82% | |||
| Earnings from Continuing Operations | 7.74% | -17.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.74% | -17.84% | |||
| EBIT | 6.55% | -8.42% | |||
| EBITDA | 8.05% | -10.45% | |||
| EPS Basic | 7.88% | -17.78% | |||
| Normalized Basic EPS | -115.82% | -13.18% | |||
| EPS Diluted | 1.53% | -14.25% | |||
| Normalized Diluted EPS | -115.82% | -13.18% | |||
| Average Basic Shares Outstanding | 0.08% | 0.07% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
